Argenx Advances Phase 3 Study for Thyroid Eye Disease Treatment

Argenx ((ARGX)) announced an update on their ongoing clinical study.

Argenx is conducting a Phase 3 study titled ‘A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.’ This study aims to assess the efficacy, safety, and tolerability of efgartigimod PH20 SC in adults with active, moderate-to-severe Thyroid Eye Disease (TED), compared to a placebo. The study is significant as it explores a potential new treatment option for TED, a condition with limited therapeutic choices.

The intervention being tested is efgartigimod PH20 SC, a combination product administered subcutaneously via a prefilled syringe. It is designed to treat TED by potentially reducing inflammation and other symptoms associated with the disease.

The study follows a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose of the study is treatment-focused, aiming to determine the effectiveness of the intervention.

The study began on March 6, 2024, with the primary completion and estimated study completion dates yet to be announced. The most recent update was submitted on August 14, 2025. These dates are crucial for investors as they indicate the study’s progress and potential timelines for results.

This clinical update could positively impact Argenx’s stock performance and investor sentiment, as successful results may lead to a new marketable treatment for TED. In the competitive landscape of pharmaceutical development, advancements in treatment options for rare diseases like TED can significantly influence market dynamics.

The study is ongoing, and further details are available on the ClinicalTrials portal.